All patients on the third and final dose level have now been dosed in Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in
XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and produced by
Each patient will be followed for 18 months with efficacy readings every six months. The primary goal is to show that XSTEM is safe, but also investigate preliminary efficacy signals, such as reduced pain, reduced degradation of articular cartilage, regeneration of damaged cartilage and improved joint function.
"All 24 osteoarthritis patients have now been treated with one dose of XSTEM. It is encouraging that the study is progressing so well and that patients experience a positive effect of the treatment at the lowest dose level. We look forward to the continued evaluation of all dose levels and to take the next step in the clinical development," says
© Modular Finance, source